Alpha 2.0
Login Register
» Authors » N C Pauly

N C Pauly

Explore the profile of N C Pauly including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 7
Citations 345
Followers 0
Related Specialties
General Medicine
Cardiology & Vascular Diseases
Top 10 Co-Authors
M E Safar
H BAGGER
J Videbaek
B A Orofiamma
G Steiner
B H MEYER
J H DE BRUIJN
C I Backhouse
B Orofiamma
P Eliasen
Published In
J Cardiovasc Pharmacol
J Hum Hypertens
N Engl J Med
Affiliations
Soon will be listed here.
Recent Articles
1.
A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group
Kober L, Torp-Pedersen C, Carlsen J, BAGGER H, Eliasen P, LYNGBORG K, et al.
N Engl J Med . 1995 Dec; 333(25):1670-6. PMID: 7477219
Background: Treatment with angiotensin-converting-enzyme (ACE) inhibitors reduces mortality among survivors of acute myocardial infarction, but whether to use ACE inhibitors in all patients or only in selected patients is uncertain....
2.
Long-term therapy with trandolapril, a new nonsulfhydryl ACE inhibitor, in hypertension: a multicenter international trial. Investigator Study Group
Backhouse C, Orofiamma B, Pauly N
J Cardiovasc Pharmacol . 1994 Jan; 23 Suppl 4:S86-90. PMID: 7527109
An international trial recruited 1,049 patients from 122 investigators. After a 2- to 4-week, single-blind placebo run-in, patients were treated unblinded for 1 year. Therapy was started with trandolapril 2...
3.
Comparison of the efficacy and safety of trandolapril and nifedipine SR in mild-to-moderate hypertension. Investigator Study Group
Steiner G, Pauly N
J Cardiovasc Pharmacol . 1994 Jan; 23 Suppl 4:S81-5. PMID: 7527108
After a single-blind, 4-week placebo run-in period, 161 patients were randomized to trandolapril 2 mg once daily (n = 54), nifedipine slow-release (SR) 20 mg twice daily (n = 55),...
4.
Double-blind comparison of the efficacy and safety of trandolapril 2 mg and hydrochlorothiazide 25 mg in patients with mild-to-moderate essential hypertension. Investigator Study Group
MEYER B, Pauly N
J Cardiovasc Pharmacol . 1994 Jan; 23 Suppl 4:S77-80. PMID: 7527107
This multicenter international trial recruited 205 patients from 16 investigators. After a 4-week, single-blind placebo run-in, patients were randomized to receive 16 weeks of trandolapril 2 mg/day (68 patients), hydrochlorothiazide...
5.
Comparison of the efficacy and safety of trandolapril and captopril for 16 weeks in mild-to-moderate essential hypertension. Investigator Study Group
Pauly N, Safar M
J Cardiovasc Pharmacol . 1994 Jan; 23 Suppl 4:S73-6. PMID: 7527106
This multicenter international trial recruited 180 patients from 27 investigators. After a 4-week, single-blind placebo run-in, patients were randomized double-blind to 16 weeks of trandolapril 4 mg o.d. or captopril...
6.
Efficacy and tolerance of trandolapril (0.5-2 mg) administered for 4 weeks in patients with mild-to-moderate hypertension. Investigator Study Group
DE BRUIJN J, Orofiamma B, Pauly N
J Cardiovasc Pharmacol . 1994 Jan; 23 Suppl 4:S60-4. PMID: 7527104
This double-blind, placebo-controlled, dose-ranging study recruited 170 patients with mild-to-moderate hypertension from nine centers. After a 4-week, single-blind, placebo run-in phase, patients were randomized in a double-blind fashion to four...
7.
Converting enzyme inhibition: dissociation between antihypertensive and arterial effects
Asmar R, Benetos A, Darne B, Pauly N, Safar M
J Hum Hypertens . 1992 Oct; 6(5):381-5. PMID: 1464895
In this study the dose-response curves reflecting the arterial and the antihypertensive effects of converting enzyme inhibition were analysed. The BP measurement (using a random zero sphygmomanometer) and its decrease...